1-BOC-7-溴吲哚 | 868561-17-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-BOC-7-溴吲哚
• 中文别名: 7-溴吲哚-1-羧酸叔丁酯
• 英文名称: tert-butyl 7-bromo-1H-indole-1-carboxylate
• 英文别名: tert-butyl 7-bromoindole-1-carboxylate
• CAS: 868561-17-5
• 化学式: C₁₃H₁₄BrNO₂
• 分子量: 296.164
• InChiKey: QKTLZTNNVUGEOY-UHFFFAOYSA-N

物化性质

• 密度：
  1.37

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-7-bromoindole
Synonyms: tert-Butyl 7-bromo-1H-indole-1-carboxylate; t-butyl 7-bromoindole-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-7-bromoindole
CAS number: 868561-17-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H14BrNO2
Molecular weight: 296.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-BOC-7-溴吲哚 在 sodium acetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 三氟乙酸 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 生成 7-(哌嗪-1-基)-1H-吲哚
  参考文献：
  名称：

  Privileged structure-based ligands for melanocortin receptors—tetrahydroquinolines, indoles, and aminotetralines

  摘要：

  Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.035
• 作为产物：
  描述：

  1-溴-2-硝基苯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.67h， 生成 1-BOC-7-溴吲哚
  参考文献：
  名称：

  吲哚氧化重排形式的全合成重氮酰胺A

  摘要：

  描述了海洋天然产物重氮酰胺A的简短正式全合成。该路线基于吲哚氧化重排，并且研究了许多选择，其中涉及在开链或大环前体氧化时酪氨酸或恶唑片段的迁移。最终途径从7-溴吲哚开始，在C-2处依次进行钯催化的恶唑片段偶联，然后在C-3处进行酪氨酸片段偶联。有了关键的2,3-二取代吲哚，大环内酰胺的形成为3,3-二取代的羟吲哚的关键氧化重排奠定了基础。尽管同时形成了不需要的吲哚异构体，但在脱保护后，该合成成功地递送了关键的羟吲哚中间体，从而完成了重氮酰胺A的正式全合成。

  DOI：

  10.1002/chem.201601605

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016055028A1

  公开（公告）日：2016-04-14

  The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中A具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的疾病中使用这些化合物和盐的方法。
• [EN] ACLY INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'ACLY ET LEURS UTILISATIONS
  申请人：NIMBUS ARTEMIS INC

  公开号：WO2020097408A1

  公开（公告）日：2020-05-14

  The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

  本发明提供了作为ATP柠檬酸裂合酶（ACLY）抑制剂的化合物、其组合物以及使用方法。
• [EN] 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10<br/>[FR] ANTAGONISTES DE 2-SULFONYLAMINO-4-HÉTÉROARYL BUTYRAMIDE DE CCR10
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009126675A1

  公开（公告）日：2009-10-15

  This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10.

  本发明涉及一种具有式（I）的化合物及其药学上可接受的盐，其中R1、R2、R4、Ar和Het如本文中所定义。该发明还涉及使用式（I）的化合物治疗通过CCR10活性介导或维持的疾病和紊乱的方法。
• 吡啶并嘧啶酮类化合物及其应用
  申请人：广州必贝特医药技术有限公司

  公开号：CN112159405A

  公开（公告）日：2021-01-01

  本发明提供了具有通式(II)所示结构的吡啶并嘧啶酮类化合物及其应用。研究证明，本发明提供的化合物可以有效抑制KRAS G12C突变。KRAS突变在肿瘤中占比很大，且目前没有获得批准药物对其进行治疗，本发明提供的化合物有潜力成为携带KRAS G12C突变的恶性肿瘤(尤其是非小细胞肺癌(NSCLC)和直结肠癌)的治疗药物，有较大的应用价值。
• Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7
  作者：Jason J. Marineau、Kristin B. Hamman、Shanhu Hu、Sydney Alnemy、Janessa Mihalich、Anzhelika Kabro、Kenneth Matthew Whitmore、Dana K. Winter、Stephanie Roy、Stephane Ciblat、Nan Ke、Anneli Savinainen、Ashraf Wilsily、Goran Malojcic、Robert Zahler、Darby Schmidt、Michael J. Bradley、Nigel J. Waters、Claudio Chuaqui

  DOI：10.1021/acs.jmedchem.1c01171

  日期：2022.1.27

  cycle and transcription. This report describes the discovery of SY-5609, a highly potent (sub-nM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126). Structure-based design was leveraged to obtain high selectivity (>4000-times the closest off target) and slow off-rate binding kinetics desirable for potent cellular activity

  CDK7 已成为肿瘤学中令人兴奋的靶点，因为它在癌细胞中失调的两个重要过程中发挥作用：细胞周期和转录。本报告描述了SY-5609的发现，这是一种高效（亚 nM CDK7 K d ）、选择性口服 CDK7 抑制剂，已于 2020 年进入临床（ClinicalTrials.gov 标识符：NCT04247126）。利用基于结构的设计来获得高选择性（> 4000倍最接近的脱靶）和缓慢的解离速率结合动力学，这是有效细胞活性所需的。最后，加入氧化膦作为非典型氢键受体有助于提供所需的效力和代谢稳定性。候选药物SY-5609对细胞中的 CDK7 具有有效的抑制作用，并且在剂量低至 2 mg/kg 时，在小鼠异种移植模型中表现出强大的功效。